John E. Reardon, Ph.D., is the Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions, Inc., a biopharmaceutical company headquartered in Research Triangle Park, NC. Prior to joining IOS Dr. Reardon was the Senior Vice President of Discovery Research Biology at GlaxoSmithKline with responsibility for the majority of biological science supporting gene-to-function-to-target-to-lead activities in the international GSK R&D organization. Dr. Reardon received his Ph.D. degree in Chemistry from The Ohio State University and did post-doctoral research with Dr. Robert Abeles at Brandeis University before beginning a career in the pharmaceutical industry. He joined Burroughs Wellcome Co. in 1987 as a Research Scientist where he contributed to the discovery and development of several anti-viral compounds.

James Brady, Ph.D., is Director of Technical Applications at MaxCyte, Inc. Since joining the company as a Senior Scientist in 2004, Dr. Brady has used his background in cell biology and molecular biology to help advance a number of the company’s key programs in the areas of cell-based therapy, vaccine manufacturing and viral vector production. Dr. Brady received a B.S. in Biology from the College of William and Mary in 1984 and a Ph.D. in Biology (Genetics) from Indiana University in 1989. He spent eight years as a postdoctoral fellow in the National Eye Institute of the National Institutes of Health in the laboratories of Dr. Joram Piatigorsky and Dr. Eric Wawrousek. After leaving N.I.H., Dr. Brady worked for four years at MetaMorphix, Inc. as a Senior Scientist and as a Group Leader in the Company’s Transgenic Livestock program, where he managed internal and external projects focused on improving livestock by modifying the activity of growth and differentiation factors. From 2001 to 2002, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders. He is coauthor on nineteen scientific papers, and he is a co-inventor on two patent applications.

Douglas Doerfler joined MaxCyte as its founding President and CEO in June 1999 and has served as a Director since December 1999. Prior to joining MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a privately owned biotechnology holding company (Novagen, Pel-Freez Clinical Systems, and Pel-Freez Biological). From May 1994 until May 1996 he was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. From 1981 until 1994, Mr. Doerfler held various executive positions with Life Technologies Inc. and its predecessor company, Bethesda Research Laboratories. At Life Technologies, Mr. Doerfler was Director of Corporate Development and World Wide Director of Instrumentation and Apparatus responsible for the company's global sequencing and separation business, including electroporation. Mr. Doerfler received his B.S. in Finance from the University of Baltimore School of Business and a certificate in Industrial Relations. He serves on the Biotechnology Industry Organization's Board of Directors, Executive Committee of the Emerging Company Section Board of Governors and the Health Section Governing Body as well as currently serving as a Director for the Maryland High Technology Council and as a Vice Chair for MdBio.